Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries

Muhsen, Ibrahim N.; Hashmi, Shahrukh K.; Niederwieser, Dietger; Agrawal, Samir; Pasquini, Marcelo C.; Atsuta, Yoshiko; Ballen, Karen K.; Seber, Adriana; Saber, Wael; Kharfan‐Dabaja, Mohamed A.; Rasheed, Walid; Okamoto, Shinichiro; Khera, Nandita; Wood, William A.; Koh, Mickey B.C.; Greinix, Hildegard; Kodera, Yoshihisa; Szer, Jeff; Horowitz, Mary M.; Weisdorf, Daniel J.; Aljurf, Mahmoud

doi:10.1038/s41409-019-0658-2

Cited by 5 publications

(1 citation statement)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although transplants have increased in recent years in LMIC, there are still 20- to 40-fold fewer HSCTs compared to the United States and Europe. 15 Still, there is no precise information in this setting, and we do not know the number of HSCT performed in LMIC.…”

Section: Why Do We Perform Outpatient Transplants?mentioning

confidence: 99%

Outpatient allogeneic hematopoietic stem-cell transplantation: a review

Gómez‐Almaguer

León

Colunga‐Pedraza

et al. 2022

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Hematopoietic stem-cell transplantation (HSCT) is usually performed in well-equipped units inside a hospital. The cost of this in-hospital transplant is usually very high; therefore, this procedure is more difficult to perform in low- and middle-income countries. Autologous outpatient HSCT is now a common procedure; however, outpatient allogeneic transplants are more complicated. Only a few centers in the world have incorporated outpatient HSCT. This transplant requires special adaptation, like a day hospital, careful selection of patients, oral medications, and the patient must live relatively close to the hospital. The results until now suggest that this outpatient transplant is factible and similar to inpatient HSCT. The objective was to review and describe the different methods and results following an outpatient allogeneic-HSCT strategy.

show abstract

Section: Why Do We Perform Outpatient Transplants?mentioning

confidence: 99%

Outpatient allogeneic hematopoietic stem-cell transplantation: a review

Gómez‐Almaguer

León

Colunga‐Pedraza

et al. 2022

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

show abstract

Monoclonal antibody biosimilars for cancer treatment

Broer,

Knapen,

de Groot

et al. 2024

iScience

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group

et al. 2021

Bone Marrow Transplant

View full text Add to dashboard Cite

Between 2008 and 2019, 58,914 hematopoietic stem cell transplantations (HSCTs) were reported to the Chinese Blood and Marrow Transplantation Registry Group (CBMTRG) throughout China. In this report, we focus on 2019 data and describe current trends in HSCT in China. There was continued growth in transplant activity in China, with a rapid increase in haploidentical HSCT. In 2019, a total of 12,323 cases of HSCT were reported from 149 transplant teams, 78% (9597 cases) were allogeneic HSCTs. Haploidentical donor (HID) HSCT accounted for 60% (5771 cases) of allogeneic HSCT. The most common indications for allogeneic HSCT for malignant disease were acute myeloid leukemia (AML) (37%) and acute lymphoblastic leukemia (ALL) (24%), and the largest proportion of non-malignant diseases comprised aplastic anemia (AA) (13%). Multiple stem cell source composed 70% of HID and 28% of MSD, which was typical in China. The BuCy based regimen (59%) was the most popular conditioning regimen for allogeneic HSCT, followed by the BuFlu based regimen (23%) and TBI-based regimen (12%). This survey clearly shows comprehensive information about the current state and recent trends for HSCT in China. Further efforts should be made to obtain detailed information.

show abstract

Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries

Cited by 5 publications

References 54 publications

Outpatient allogeneic hematopoietic stem-cell transplantation: a review

Outpatient allogeneic hematopoietic stem-cell transplantation: a review

Monoclonal antibody biosimilars for cancer treatment

Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group

Contact Info

Product

Resources

About